Navigation Links
Tianyin's Dr. James Jiayuan Tong is Invited to Speak at the CFO China Summit 2011 on January 19, 2011 at the St. Regis Hotel, Beijing

BEIJING, Nov. 16, 2010 /PRNewswire-Asia-FirstCall/ -- Dr. James Jiayuan Tong, Chief Financial Officer, Chief Business & Development Officer and Director of Tianyin Pharmaceutical (NYSE Amex: TPI) is invited to present at CFO China Summit 2011 which will be held at the St. Regis Hotel at 21 Jianguomenwai Avenue, Beijing 100020, China on January 19, 2011.

Dr. Tong will present in two panel discussions:

  1. Implementing Effective Working Capital Management Strategies in China at 11:15 am
  2. Understanding How CFOs in China Can Raise Funds through the Capital Markets at 12:00 noon

About the CFO China Summit 2011

The CFO China Summit 2011, held in Beijing on January 19th, 2011, is part of the successful CFO Asia Summit series that gathers leading financial drivers in China's economy to discuss key challenges currently faced by CFOs in China. Supported by the Wall Street Journal, this summit draws the top financial minds to discuss the core financial and organizational issues and develop effective strategies and solutions. The Summit will be held in a panel discussion format in order to ensure maximum engagement and interaction amongst the speakers and delegates, for enhanced idea generation and sharing of experiences gathered from their day-to-day work.

Key themes for the CFO China Summit 2011:

  1. Financial risk management – Formulating strategies to minimize investment risks and generate higher returns on investments;
  2. Working capital management – Ensuring healthy cash flow to finance growth in the business;
  3. Talent management – Strategies to attract, train and retain qualified talent in the finance team;
  4. Standardization of operating procedures in the finance function;
  5. Ensuring sustainable growth amidst economic uncertainties – Developing approaches to buffer the changing economic policies for enhanced organizational stability.

More information regarding the Summit can be found on

About Tianyin Pharmaceutical

Tianyin Pharmaceutical Co., Inc., headquartered at Chengdu, China, specializes in the development, manufacturing, marketing and sale of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. Tianyin currently manufactures and markets a comprehensive portfolio of 56 products, 23 of which are listed in the highly selective National Reimbursement List, 7 are included in the Essential Drug List of China. Tianyin has a pipeline of 10 products pending SFDA approval targeting cardiovascular conditions, women's health, immune system and respiratory disorders. Tianyin has an extensive nationwide distribution network with 730 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.For more information, please contact:Investors Contact:James Jiayuan Tong M.D. Ph.D.Chief Financial Officer, Chief Business & Development OfficerDirectorTianyin Pharmaceutical Co., Inc. Web: Email: Tel:
+86-28-8551-6696 (Chengdu, China)+1-949-350-6999 (U.S.)+86-134 36 550011 (China)Address:23rd Floor Unionsun Yangkuo PlazaNo. 2, Block 3, South Renmin RoadChengdu, 610041China

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
2. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
3. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
4. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
5. Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia
6. Professors Raphael Haftka and C. T. Sun to receive AIAA-ASC James H. Starnes, Jr. Award
7. Professors Raphael Haftka and C. T. Sun to receive AIAA-ASC James H. Starnes Jr. Award
8. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
9. Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors
10. Microfluidics Chairman James N. Little, Ph.D., Announces Retirement from Board of Directors
11. Rensselaer Polytechnic Institute professor James Lu garners award for research on 3-D computer chips
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
(Date:11/24/2015)... BC (PRWEB) , ... November 24, 2015 , ... ... our customer, OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology Fast ... Technologies’ Texas facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device that ...
(Date:11/24/2015)... HemoShear Therapeutics, LLC, a privately held ... disorders, announced today the appointment of H. ... (BOD). Mr. Watkins is the former president and ... and also served as the chairman of the ... Chairman and CEO of HemoShear Therapeutics. "The combination ...
(Date:11/24/2015)... ... ... Laboratories is pleased to announce that it has completed construction on a new ... 61, USP 62 and USP 51 testing specific to raw materials and will enable ... by one supplier. Management has formally announced that the facility will be ...
Breaking Biology Technology:
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
Breaking Biology News(10 mins):